产品名称
奥芬那君 盐酸盐, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C18H23NO.ClH/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16;/h4-12,18H,13-14H2,1-3H3;1H
SMILES string
Cl.CN(C)CCOC(c1ccccc1)c2ccccc2C
InChI key
UQZKYYIKWZOKKD-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
orphenadrine
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Gene Information
正在寻找类似产品? 访问 产品对比指南
Other Notes
Sales restrictions may apply.
Biochem/physiol Actions
毒蕈碱型受体拮抗剂;H1 组胺受体拮抗剂;肌肉松弛剂。据报道,奥芬那君还可抑制去甲肾上素转运蛋白并且阻塞 NMDA 受体离子通道。
Application
Orphenadrine hydrochloride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Jean-François Desaphy et al.
Experimental neurology, 255, 96-102 (2014-03-13)
Although the sodium channel blocker mexiletine is considered the first-line drug in myotonia, some patients experiment adverse effects, while others do not gain any benefit. Other antimyotonic drugs are thus needed to offer mexiletine alternatives. In the present study, we
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持